Question · asked by 1 review

LAMA vs placebo: Lung function: FEV1 mL (change from baseline)

Population
adults and children with cystic fibrosis
Intervention
LAMA
Comparison
placebo
Outcome
Lung function: FEV1 mL (change from baseline)

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
LAMAs vs placebo
FEV1: mean change from baseline (L) · adults and children with cystic fibrosis
Long‐acting inhaled bronchodilators for cystic fibrosis (2017) · Cochrane Headline outcomes only
no estimate extracted1 study · 34 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Long‐acting inhaled bronchodilators for cystic fibrosis
2017 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.